Zorab DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing the movement of stomach contents into the intestines, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Zorab DSR Capsule offers both symptomatic relief and promotes mucosal healing by reducing acid load and improving gastric emptying. This combination is particularly beneficial in patients experiencing delayed gastric emptying alongside acid-related disorders. Zorab DSR Capsule should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. It is contraindicated in patients with known hypersensitivity to either component, and caution is advised in those with hepatic or renal impairment. Common adverse effects may include dry mouth, headache, and gastrointestinal disturbances.